Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –
Vaxart operating margin
Operating margin is operating income as a percentage of revenue.
Vaxart's operating margin for the twelve months ending Sep 30, 2026 was 16.6%. For fiscal 2025 it was 7.6%, against -231.0% the year before. The highest annual figure on record is 7.6% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.6% | +238.6 |
| FY2024 | Dec 31, 2024 | -231.0% | +898.5 |
| FY2023 | Dec 31, 2023 | -1129.5% | +105961.1 |
| FY2022 | Dec 31, 2022 | -107090.7% | −98934.6 |
| FY2021 | Dec 31, 2021 | -8156.1% | −7410.4 |
| FY2020 | Dec 31, 2020 | -745.7% | −585.6 |
| FY2019 | Dec 31, 2019 | -160.1% | +363.0 |
| FY2018 | Dec 31, 2018 | -523.1% | −252.1 |
| FY2016 | Jun 30, 2016 | -271.0% | −191.7 |
| FY2015 | Jun 30, 2015 | -79.3% | −62.5 |
| FY2014 | Jun 30, 2014 | -16.7% | +49.0 |
| FY2013 | Jun 30, 2013 | -65.8% | +46.5 |
| FY2012 | Jun 30, 2012 | -112.3% | +59.1 |
| FY2009 | Dec 26, 2009 | -171.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | -162.7% | −152.0 |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -48.5% | −11.7 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | 13.2% | +84.7 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | 53.2% | +128.8 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -10.8% | +282.6 |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -36.8% | +217.2 |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -71.5% | +1032.1 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -75.7% | +445.1 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -293.4% | +554.8 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -254.0% | +1443.6 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -1103.6% | +2684.8 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -520.8% | +141015.6 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -848.3% | +28300.0 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -1697.6% | +31025.4 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -3788.4% | +4837.1 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -141536.4% | −127451.5 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -29148.2% | −26082.8 |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -32723.0% | −28969.9 |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -8625.5% | −5761.7 |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -14084.8% | −12454.6 |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -3065.4% | −3041.5 |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -3753.1% | −3609.4 |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -2863.8% | −1825.4 |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -1630.2% | +4248.6 |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -23.9% | −15.6 |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -143.7% | +93.2 |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -1038.3% | +1054.2 |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -5878.8% | −4600.0 |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -8.3% | +252.2 |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -236.9% | +879.8 |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -2092.5% | −1994.4 |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -1278.8% | −896.4 |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -260.5% | +133.6 |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -1116.7% | −628.9 |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -98.1% | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -382.4% | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -394.1% | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -487.8% | – |
See a number that looks wrong?